These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16263868)

  • 21. Sudden akathisia after a ziprasidone dose reduction.
    Oral ET; Altinbas K; Demirkiran S
    Am J Psychiatry; 2006 Mar; 163(3):546. PubMed ID: 16513883
    [No Abstract]   [Full Text] [Related]  

  • 22. Possible ziprasidone-induced mania.
    Larson MF; Hauser A
    J Am Acad Child Adolesc Psychiatry; 2003 Sep; 42(9):1012; discussion 1012-3. PubMed ID: 12964565
    [No Abstract]   [Full Text] [Related]  

  • 23. Ziprasidone induced symptomatic bradycardia: a case report.
    Menon V; Kattimani S; Ayyanar S
    Aust N Z J Psychiatry; 2011 Sep; 45(9):789. PubMed ID: 21668298
    [No Abstract]   [Full Text] [Related]  

  • 24. Aripiprazole-induced improvement in tardive dyskinesia.
    Duggal HS
    Can J Psychiatry; 2003 Dec; 48(11):771-2. PubMed ID: 14733461
    [No Abstract]   [Full Text] [Related]  

  • 25. Parkinsonism with intramuscular ziprasidone.
    Bilal L; Tsai C; Gasper JJ; Ndlela JC
    Am J Psychiatry; 2005 Dec; 162(12):2392-3. PubMed ID: 16330610
    [No Abstract]   [Full Text] [Related]  

  • 26. Ziprasidone approved.
    Hirsch M
    Harv Ment Health Lett; 2001 Jun; 17(12):8. PubMed ID: 11439926
    [No Abstract]   [Full Text] [Related]  

  • 27. Aripiprazole resolves amisulpride and ziprasidone-induced hyperprolactinemia.
    Saitis M; Papazisis G; Katsigiannopoulos K; Kouvelas D
    Psychiatry Clin Neurosci; 2008 Oct; 62(5):624. PubMed ID: 18950388
    [No Abstract]   [Full Text] [Related]  

  • 28. Transient agranulocytosis associated with ziprasidone in a 45-year-old man on hemodialysis.
    Iskandar JW; Vance JE; Kablinger A; Kavuru B
    J Clin Psychopharmacol; 2015 Jun; 35(3):347-8. PubMed ID: 25874914
    [No Abstract]   [Full Text] [Related]  

  • 29. Tardive dystonia due to aripiprazole use in a neuroleptic-naive patient.
    Friedman JH
    J Clin Psychiatry; 2010 May; 71(5):652-3. PubMed ID: 20492857
    [No Abstract]   [Full Text] [Related]  

  • 30. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone.
    Yang SH; McNeely MJ
    Am J Psychiatry; 2002 Aug; 159(8):1435. PubMed ID: 12153844
    [No Abstract]   [Full Text] [Related]  

  • 31. High-dose ziprasidone-induced acute dystonia.
    Rosenfield PJ; Girgis RR; Gil R
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):546-7. PubMed ID: 17123682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A case report with ziprasidone-induced catatonic symptoms.
    Markham-Abedi C; McNeely C; de Leon J
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):476-7. PubMed ID: 18070860
    [No Abstract]   [Full Text] [Related]  

  • 33. Ziprasidone-induced tardive dyskinesia in a patient without known risk factors.
    Sinha P; Rao R; Sharan P
    Natl Med J India; 2007; 20(5):271-2. PubMed ID: 18254531
    [No Abstract]   [Full Text] [Related]  

  • 34. [Ziprasidone and dementia].
    Aakhus E
    Tidsskr Nor Laegeforen; 2004 Aug; 124(16):2155-6; author reply 2155-6. PubMed ID: 15334150
    [No Abstract]   [Full Text] [Related]  

  • 35. Ziprasidone induction of hypomania in depression?
    Davis R; Risch SC
    Am J Psychiatry; 2002 Apr; 159(4):673-4. PubMed ID: 11925314
    [No Abstract]   [Full Text] [Related]  

  • 36. Hypomanic episodes after receiving ziprasidone: an unintended "on-off-on" course of treatment.
    Brieger P
    J Clin Psychiatry; 2004 Jan; 65(1):132-5. PubMed ID: 14744182
    [No Abstract]   [Full Text] [Related]  

  • 37. Sudden death in a patient with Tourette syndrome during a clinical trial of ziprasidone.
    Scahill L; Blair J; Leckman JF; Martin A
    J Psychopharmacol; 2005 Mar; 19(2):205-6. PubMed ID: 15728441
    [No Abstract]   [Full Text] [Related]  

  • 38. Hyperosmolar hyperglycemic state associated with ziprasidone treatment: a case report.
    Létourneau G; Abdel-Baki A; Dubreucq S; Mahone M; Granger B
    J Clin Psychopharmacol; 2011 Oct; 31(5):671-3. PubMed ID: 21881458
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia.
    Gao K; Pappadopulos E; Karayal ON; Kolluri S; Calabrese JR
    J Clin Psychopharmacol; 2013 Jun; 33(3):425-31. PubMed ID: 23609405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: a diagnostic challenge.
    Gray NS
    Hum Psychopharmacol; 2004 Apr; 19(3):205-7. PubMed ID: 15079855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.